BIOMIMESYS® has taken place in the panel of the future medicine on the 27th of September. The next step has arrived, and Nathalie Maubon CEO of HCS Pharma has taken BIOMIMESYS® all the way to Asia.
Our innovative and reliable 3D cell culture system is adapted to high throughput formats and as a reproducible matrix. Allowing the model different aspects of tissue environment, the BIOMIMESYS® product range also now has the advantage to be animal-free, therefore even more adapted to 3Rs than ever.
We are glad to be a part of the round table to present moreover about BIOMIMESYS® and impulse our extracellular matrix as the next unmissable tools in the medical research field.
0 Comments